S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CABA

Cabaletta Bio (CABA) Stock Forecast, Price & News

$1.42
-0.20 (-12.35%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.42
$1.68
50-Day Range
$1.22
$2.29
52-Week Range
$1.17
$14.95
Volume
74,914 shs
Average Volume
179,211 shs
Market Capitalization
$41.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.53
30 days | 90 days | 365 days | Advanced Chart
Receive CABA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

Cabaletta Bio logo

About Cabaletta Bio

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CABA
Fax
N/A
Employees
53
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.68 per share

Profitability

Net Income
$-46.29 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
26,395,000
Market Cap
$41.15 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/22/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.04 out of 5 stars

Medical Sector

544th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

87th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Cabaletta Bio (NASDAQ:CABA) Frequently Asked Questions

Is Cabaletta Bio a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cabaletta Bio stock.
View analyst ratings for Cabaletta Bio
or view top-rated stocks.

When is Cabaletta Bio's next earnings date?

Cabaletta Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Cabaletta Bio
.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.08.
View Cabaletta Bio's earnings history
.

What price target have analysts set for CABA?

5 Wall Street analysts have issued 1-year price objectives for Cabaletta Bio's stock. Their forecasts range from $11.00 to $28.00. On average, they expect Cabaletta Bio's share price to reach $18.20 in the next year. This suggests a possible upside of 1,181.7% from the stock's current price.
View analysts' price targets for Cabaletta Bio
or view top-rated stocks among Wall Street analysts.

Who are Cabaletta Bio's key executives?
Cabaletta Bio's management team includes the following people:
  • Dr. Steven A. Nichtberger M.D., Co-Founder, Chairman, CEO & Pres (Age 61, Pay $871.16k)
  • Dr. Gwendolyn K. Binder Ph.D., Pres of Science & Technology (Age 47, Pay $625.13k)
  • Dr. David J. Chang M.D., M.P.H., Chief Medical Officer (Age 59, Pay $638.63k)
  • Dr. Michael C. Milone M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Dr. Aimee Payne M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. Anup Marda M.B.A., Chief Financial Officer (Age 45)
  • Dr. Samik Basu M.D., Chief Scientific Officer
  • Mr. Michael Gerard, Gen. Counsel
  • Ms. Heather Harte-Hall M.Sc., Chief Compliance Officer
  • Ms. Martha O'Connor, Chief HR Officer
What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an IPO on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

What is Cabaletta Bio's stock symbol?

Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.20%), Kynam Capital Management LP (2.46%), Renaissance Technologies LLC (0.80%), Acadian Asset Management LLC (0.59%), CI Investments Inc. (0.51%) and Harbor Capital Advisors Inc. (0.48%).
View institutional ownership trends for Cabaletta Bio
.

Which major investors are selling Cabaletta Bio stock?

CABA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Virtu Financial LLC, Walleye Capital LLC, Kynam Capital Management LP, Harbor Capital Advisors Inc., Dimensional Fund Advisors LP, Hsbc Holdings PLC, and Group One Trading L.P..
View insider buying and selling activity for Cabaletta Bio
or view top insider-selling stocks.

Which major investors are buying Cabaletta Bio stock?

CABA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Vanguard Group Inc., CI Investments Inc., Veritable L.P., Powell Investment Advisors LLC, Bank of New York Mellon Corp, and Dynamic Technology Lab Private Ltd.
View insider buying and selling activity for Cabaletta Bio
or or view top insider-buying stocks.

How do I buy shares of Cabaletta Bio?

Shares of CABA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cabaletta Bio's stock price today?

One share of CABA stock can currently be purchased for approximately $1.42.

How much money does Cabaletta Bio make?

Cabaletta Bio has a market capitalization of $41.15 million. The company earns $-46.29 million in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Cabaletta Bio have?

Cabaletta Bio employs 53 workers across the globe.

What is Cabaletta Bio's official website?

The official website for Cabaletta Bio is www.cabalettabio.com.

How can I contact Cabaletta Bio?

Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The company can be reached via phone at 267-759-3100 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.